Levofloxacin kabi    (DrugBank: Levofloxacin)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,592 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-000955-16-AT
(EUCTR)
28/01/202007/01/2020Characterization of lung concentrations of the antibiotics piperacillin/tazobactam and levofloxacinPulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy Pneumonia;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]Trade Name: Piperacillin/Tazobactam Kabi - Fresenius Kabi Austria
INN or Proposed INN: piperacillin
Other descriptive name: PIPERACILLIN
INN or Proposed INN: tazobactam
Other descriptive name: TAZOBACTAM
Trade Name: Levofloxacin Kabi
INN or Proposed INN: levofloxacin
Other descriptive name: LEVOFLOXACIN HEMIHYDRATE
Medical University of ViennaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
18Phase 4Austria